Cory Renauer
Value, research analyst, biotech, small-cap

Alnylam's 5x15 Progress Report

RNA interference drug development

Alnylam Pharmaceuticals (NASDAQ:ALNY) is a Cambridge, Massachusetts company focused on the development and commercialization of novel RNAi therapeutics for the treatment of diseases with high unmet medical need and genetically defined targets.

Alnylam expects to have five RNAi programs in clinical development, or in commercial stages, by the end of 2015. The company's core product strategy, called "Alnylam 5x15", involves developing all five program candidates with the following shared characteristics:

    Specificity for genetically defined target and disease. Potential to significantly impact high unmet need populations. Ability to leverage the company's existing RNAi delivery platform. Opportunity to monitor an early biomarker in Phase 1 clinical trials for human proof of concept. Existence of clinically relevant ...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details